Objective
Human Papillomavirus Type 16 (HPV16), the paradigm cancer-causing HPV type, is a small, nonenveloped, DNA virus characterized by its complex life cycle coupled to differentiation of squamous epithelia. Due to this complexity, how HPV16 infects cells is an understudied field of research. Our previous work to define the cellular pathways that are hijacked for initial infection revealed uptake by a novel endocytosis mechanism, and the requirement for mitosis for nuclear delivery. Our findings indicated that nuclear envelope breakdown was required to access the nuclear space, and that the virus associated with mitotic chromatin during metaphase. This prolonged mitosis, a process beneficiary for infection. The viral L2 protein as part of incoming viruses mimics this on its own. The aim of this proposal is to reveal how HPV16 differentially modulates or takes advantage of the mitotic machinery for nuclear import in cells, tissues or during aging, and whether malignant cellular consequences arise. On the viral side, we will define the minimal properties of L2 to mediate association with cell chromatin and mitosis prolongation. On the cellular side, we will identify the protein(s) that mediate recruitment, and how it occurs in a detailed temporal/spatial manner. To elucidate the mechanism of mitotic prolongation and consequences thereof, we will identify which regulatory complex of mitosis is targeted, how it is induced, and whether it causes DNA damage or segregation errors. Finally, we will ascertain the influence of tissue differentiation and aging on this process. Using systems biology, proteomics, virology, cell biology, biochemistry, and a wide range of microscopy approaches we will unravel the complex interactions between HPV and the host cell mitosis machinery. In turn, as viruses often serve as valuable tools to study cell function, this work is likely to uncover new insights into how cells spatially and temporally regulate mitosis in differentiation and aging.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciences biological sciences microbiology virology
- natural sciences biological sciences genetics DNA
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences clinical medicine oncology cervical cancer
- medical and health sciences health sciences infectious diseases DNA viruses
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
ERC-COG - Consolidator Grant
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2015-CoG
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
48149 MUENSTER
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.